[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657829":3},{"organization":4,"outcomesModule":7,"designInfo":108,"detailedDescription":107,"studyPopulation":111,"armGroups":112,"interventions":117,"overallOfficials":107,"centralContacts":107,"locations":123,"responsibleParty":142,"collaborators":107,"id":146,"slug":147,"hasResults":148,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":107,"eligibilityCriteria":152,"healthyVolunteers":148,"sex":153,"minAge":154,"maxAge":107,"enrollmentInfo":155,"targetDuration":107,"studyType":158,"phases":107,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":166,"whyStopped":107,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"University of Barcelona","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":107},[9],{"measure":10,"description":11,"timeFrame":12},"Clinical Success Following Flapless Treatment of Peri-Implantitis","Clinical success, recorded dichotomously (success\u002Fno success), assessed at six sites per implant. An implant is classified as a clinical success when probing depth (PD) is ≤5 mm at all six sites, bleeding on probing is present at, at most, one site and presents as an isolated spot rather than a line or profuse bleeding, and suppuration is absent at all sites.","6 weeks, 12 weeks, 6 months, 9 months, and 12 months after treatment",[14,18,21,24,27,30,33,36,39,42,45,48,51,54,58,62,65,68,71,74,77,81,84,87,90,94,97,100,103],{"measure":15,"description":16,"timeFrame":17},"Age (Years)","Age at inclusion, recorded in completed years.","Baseline (T0)",{"measure":19,"description":20,"timeFrame":17},"Sex (Male\u002FFemale)","Sex of participants.",{"measure":22,"description":23,"timeFrame":17},"Smoking Status (Never Smoker\u002FFormer Smoker\u002FCurrent Smoker)","Smoking status classified as never smoker, former smoker, or current smoker. In current and former smokers, cumulative smoking exposure will be recorded in pack-years; in current smokers, daily cigarette consumption will also be recorded.",{"measure":25,"description":26,"timeFrame":17},"Periodontal Diagnosis (Stage I-IV; Grade A-C)","Periodontal diagnosis according to the classification of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.",{"measure":28,"description":29,"timeFrame":17},"Arch (Maxilla\u002FMandible)","Location of the implant by dental arch.",{"measure":31,"description":32,"timeFrame":17},"Location (Anterior\u002FPremolar\u002FMolar)","Implant location within the arch.",{"measure":34,"description":35,"timeFrame":17},"Implant Type (Bone Level\u002FTissue Level)","Type of implant according to its design.",{"measure":37,"description":38,"timeFrame":17},"Implant Length and Diameter (mm)","Implant length and diameter, recorded in millimeters.",{"measure":40,"description":41,"timeFrame":17},"Surface Type (Machined\u002FRough)","Implant surface type.",{"measure":43,"description":44,"timeFrame":17},"Implant-Abutment Connection Type (Internal\u002FExternal)","Type of connection between implant and abutment.",{"measure":46,"description":47,"timeFrame":17},"Time in Function (Years)","Time elapsed since implant placement, recorded in years.",{"measure":49,"description":50,"timeFrame":17},"Prosthesis Type (Single-Unit\u002FPartial\u002FMultiple)","Type of implant-supported prosthesis.",{"measure":52,"description":53,"timeFrame":17},"Intermediate Abutment (Yes\u002FNo)","Presence of an intermediate abutment.",{"measure":55,"description":56,"timeFrame":57},"Prosthetic Modification During Treatment (Yes\u002FNo)","Whether a prosthetic modification was performed during the flapless treatment visit.","Flapless treatment visit (T-treatment)",{"measure":59,"description":60,"timeFrame":61},"Modified Plaque Index (0-3)","Presence of plaque, recorded at six sites per implant using the modified plaque index (Mombelli et al., 1987).","Baseline (T0), and at 6 and 12 weeks, and 6, 9, and 12 months (T1-T5)",{"measure":63,"description":64,"timeFrame":61},"Probing Depth (mm)","Distance, in millimeters, from the mucosal margin to the base of the peri-implant pocket, measured without the prosthesis in place, recorded at six sites per implant using a PCP-UNC 15 periodontal probe.",{"measure":66,"description":67,"timeFrame":61},"Bleeding on Probing (Present\u002FAbsent)","Presence or absence of bleeding on probing, recorded at six sites per implant.",{"measure":69,"description":70,"timeFrame":61},"Suppuration on Probing (Present\u002FAbsent)","Presence or absence of suppuration on probing, recorded at six sites per implant.",{"measure":72,"description":73,"timeFrame":57},"Implant-Mucosa Distance (mm)","Distance between the mucosal margin and the implant shoulder, measured after prosthesis removal at six sites per implant. Recorded as positive when the mucosal margin is apical to the implant shoulder, and negative when coronal to it.",{"measure":75,"description":76,"timeFrame":57},"Keratinized Mucosa (mm)","Distance between the mucosal margin and the mucogingival junction, measured at six sites per implant.",{"measure":78,"description":79,"timeFrame":80},"Retreatment Performed (Yes\u002FNo)","Whether retreatment (re-instrumentation without adjunctive systemic antibiotics) was performed, and timing.","12 weeks, and 6, 9, and 12 months (T2-T5)",{"measure":82,"description":83,"timeFrame":80},"Need for Surgical Peri-Implant Treatment (Yes\u002FNo)","Whether additional surgical peri-implant treatment was required, and timing.",{"measure":85,"description":86,"timeFrame":80},"Implant Loss (Yes\u002FNo)","Whether the implant was lost\u002Fextracted, and timing.",{"measure":88,"description":89,"timeFrame":17},"Radiographic Defect Morphology (Supracrestal\u002FIntrabony\u002FCombined)","Morphology of the radiographic bone defect, classified as supracrestal, intrabony, or combined, assessed on periapical radiographs obtained using the long-cone paralleling technique and analyzed with ImageJ® software after calibration using the known implant length.",{"measure":91,"description":92,"timeFrame":93},"Radiographic Bone Level (mm)","Distance, in millimeters, between the implant shoulder and the base of the bone defect, assessed on periapical radiographs obtained using the long-cone paralleling technique and analyzed with ImageJ® software after calibration using the known implant length.","Baseline (T0), and at 6 and 12 months (T3, T5), or at any other visit if clinically necessary",{"measure":95,"description":96,"timeFrame":17},"Intrabony Defect Depth (mm)","Depth of the intrabony component of the radiographic defect, assessed on periapical radiographs.",{"measure":98,"description":99,"timeFrame":17},"Intrabony Defect Width (mm)","Width of the intrabony component of the radiographic defect, assessed on periapical radiographs.",{"measure":101,"description":102,"timeFrame":17},"Intrabony Defect Angle (º)","Angle of the intrabony component of the radiographic defect, assessed on periapical radiographs.",{"measure":104,"description":105,"timeFrame":106},"Treatment Trajectory (Success Without Retreatment\u002FSuccess After Retreatment\u002FPersistent Failure at 12 Months\u002FSurgical Treatment or Implant Loss)","Implant status at the 12-month outcome, classified as: success without retreatment; success after retreatment; persistent failure at 12 months; or surgical treatment\u002Fimplant loss. An implant is considered a treatment failure if classified as either persistent failure at 12 months or surgical treatment\u002Fimplant loss.","12 months (T5)",null,{"allocation":107,"interventionModel":107,"interventionModelDescription":107,"primaryPurpose":107,"observationalModel":109,"timePerspective":110,"maskingInfo":107},"COHORT","PROSPECTIVE","Adult patients with at least one dental implant in function for at least 12 months, diagnosed with peri-implantitis according to the 2017 World Workshop criteria, treated at the Hospital Odontològic Universitat de Barcelona.",[113],{"label":114,"type":107,"description":107,"interventionNames":115},"Flapless treatment",[116],"Procedure: Flapless non-surgical treatment of peri-implantitis",[118],{"type":119,"name":120,"description":121,"armGroupLabels":122,"otherNames":107},"PROCEDURE","Flapless non-surgical treatment of peri-implantitis","Non-surgical flapless treatment consisting of oral hygiene motivation and instructions, removal of the implant-supported prosthesis when possible, modification of the emergence profile when indicated, supra- and submucosal mechanical debridement using ultrasonic devices with periodontal tips and steel curettes, removal of granulation tissue, and curettage of the peri-implant mucosa. Followed by chlorhexidine gel twice daily for 15 days and systemic antibiotic therapy (metronidazole 500 mg three times daily for 7 days, or azithromycin 500 mg once daily for 3 days in case of allergy\u002Fcontraindication)",[114],[124],{"facility":125,"status":107,"city":126,"state":127,"zip":107,"country":128,"countryCode":129,"cosmosGeoPoint":130,"geoPoint":135,"contacts":136},"Hospital Odontològic Universitat de Barcelona","L'Hospitalet de Llobregat","Barcelona","Spain","ES",{"type":131,"coordinates":132},"Point",[133,134],2.10028,41.35967,{"lat":134,"lon":133},[137],{"name":138,"role":139,"phone":140,"phoneExt":107,"email":141},"Camps Font","CONTACT","+34 620 189 707","phernade30@alumnes.ub.edu",{"type":143,"investigatorFullName":144,"investigatorTitle":145,"investigatorAffiliation":5,"oldNameTitle":107,"oldOrganization":107},"PRINCIPAL_INVESTIGATOR","Octavi Camps-Font","Associate Professor","100657829","timing-of-success-evaluation-after-flapless-treatment-of-peri-implantitis-100657829",false,"NCT07844642","Timing of Success Evaluation After Flapless Treatment of Peri-Implantitis","Timing of Success Evaluation Following Flapless Treatment of Peri-Implantitis: A Prospective Case Series","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* General health status compatible with dental treatment (ASA I-II).\n* Ability to understand the study, sign the informed consent form, and comply with the follow-up protocol.\n* Presence of one or more dental implants in function for at least 12 months, placed at any center, regardless of connection type or the presence of platform switching.\n* Screw-retained implant-supported prostheses (single-unit, partial, or complete).\n* Presence of at least one implant diagnosed with peri-implantitis, according to the criteria of the 2017 Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.\n\nExclusion Criteria:\n\n* Refusal to participate in the study or inability to provide informed consent.\n* Non-acceptance of the proposed treatment.\n* Pregnancy or breastfeeding.\n* Treatment with drugs or presence of diseases that may alter the healing of peri-implant tissues or interfere with the response to treatment (e.g., immunosuppressants, systemic corticosteroids at immunosuppressive doses, or treatment with antiresorptive or antiangiogenic agents).\n* Implants restored with cemented prostheses.\n* Implants with mobility or with radiographic bone loss exceeding 50%.\n* Surgical or non-surgical peri-implant treatment of the affected implant within the previous 12 months.\n* Systemic antibiotic treatment within the previous 3 months.","ALL","18 Years",{"count":156,"type":157},60,"ESTIMATED","OBSERVATIONAL","Peri-implantitis is an inflammatory disease around dental implants that causes progressive loss of the bone supporting the implant. Current clinical guidelines recommend treating it first with a non-surgical approach and then checking treatment success, usually between 6 and 12 weeks later. However, it is not known whether this is the best time to check the results, since no previous studies have compared different follow-up time points.\n\nThis study will follow patients with peri-implantitis who receive the same non-surgical, flapless treatment. Their implants will be checked at five different times after treatment (6 and 12 weeks, and 6, 9, and 12 months) to see how the clinical outcome changes over time. The main goal is to find out how treatment success evolves at these different time points, and whether the results seen early (at 6 weeks) match the final results seen at 12 months",[161],"Peri-implantitis",[163,114,164,165],"Non-surgical treatment","Treatment success","Re-evaluation timing","NOT_YET_RECRUITING","2026-09-22",{"date":169,"type":170},"2026-09-28","ACTUAL",{"date":172,"type":157},"2026-10",{"date":174,"type":157},"2028-09",{"name":5,"class":6},1]